Cardiovascular

Therapies for heart disease, stroke, and vascular conditions including novel lipid-lowering and anti-thrombotic agents.

Companies

Pipeline Drugs

2016

Key People

2227

Cardiovascular Pipeline (2016 drugs)

Commercial: 378Pre-clinical: 226Approved: 118Preclinical: 115Phase 3: 107Development: 91Phase 2: 79Phase 1: 68Research: 40Marketed: 31Phase III: 29Post-Market: 16Phase 1/2: 16Not Specified: 14Pivotal: 13Discovery: 13Launched: 12Pivotal Trial: 11Research/Development: 11Early-stage Clinical: 11Phase II: 10Unknown: 10Phase 2/3: 9Development/Commercial: 9Not Disclosed: 8Phase I: 8Pre-clinical/Development: 7Investigational: 7Clinical: 6Various: 6Phase1: 6Phase 2b: 5Clinical Development: 5Commercial Launch: 5ANDA Approved: 5Feasibility: 5Early Feasibility: 5Pre-clinical/Clinical: 5Development/Validation: 5Phase I/II: 5ANDA Filed/Approved: 5Marketed (Global): 5Under Development: 4Regulatory Submission: 4Clinical Research: 4Pre‑clinical: 4N/A: 4Regulatory Review: 4Commercial Model: 4Clinical Validation: 4Commercial/Development: 4Clinical Trials: 4Clinical Evidence: 4Phase 2A: 4Randomized Controlled Trial: 3Post-Market Registry: 3Observational Study: 3Discovery/Development: 3Phase 2a: 3Early Development: 3Platform/Tool Development: 3Approved/Commercial: 3Commercial (CE Mark): 3NA: 3Service Offering: 3Commercial Development: 3Early Feasibility Study: 3Research/Preclinical Tools: 3RUO Kit: 3Clinical Study: 3Phase 2B/3: 3Not Disclosed (Sponsor-led): 3Regulatory: 3Discovery/Validation: 3Commercial (Iterative Development): 3Phase 4: 3Discovery/Preclinical: 3Research/Pre‑clinical: 3Approved / Lifecycle: 3Clinical Investigation: 3Human Clinical: 3commercial: 2Design & Development: 2Filed: 2Research/Discovery: 2Phase IIb/III: 2R&D: 2Pre-clinical/Feasibility: 2Pivotal Study: 2Pre-Clinical: 2Commercial/Diagnostic: 2Implementation: 2Phase 1b/2a: 2FDA-Cleared: 2Various (Typically Phase 2-4): 2Commercial (Post-market): 2Registry: 2Phase 3 (IDE): 2Pre-market: 2Strategic Development: 2Technology Development: 2Pre-commercial: 2Research/Preclinical: 2Commercial (Ongoing Development): 2Clinical Trial: 2Feasibility / First-in-Human: 2Commercial Deployment: 2Pre-launch: 2First-in-Human: 2Development/ANDA Filing: 2Research/Pre-clinical: 2Clinical Stage (Phase not specified): 2Commercial Expansion: 2Pre-clinical (inferred): 2Early Research: 2Feasibility Study: 2Phase2: 2Pre-clinical/Planning: 2Phase 1b: 2Pre-clinical / Early Clinical: 2Early Clinical: 2Research/Validation: 2Cleared: 2Clinical Feasibility: 2Preclinical to Commercial: 2Phase 1/2a: 2Commercial (RUO): 2Phase 3/4: 2Discovery/Optimization: 2Pre-approval: 2Development/Marketed: 2Clinical-stage (phase unspecified): 2Commercial (licensed): 2Phase 2 (Observational Clinical Study): 2Regulatory Approved: 2Approved / Phase III: 2Phases I-III & Commercial: 2Development & Commercial: 2Preclinical/Discovery: 2Phase II/III: 2FDA Approved: 2Completed: 2Commercial / Ongoing Research: 2Various (Partner-led): 2Pre-market (NMPA under review): 2Phase 3-ready: 2pre‑clinical: 1Marketed / NDA: 1ANDA / Marketed: 1Research / Pre-clinical: 1Application Submitted / BE Stage: 1Preclinical/Exploratory: 1Concept / Early Development: 1ANDA Filed / Development: 1ANDA Pending / Development: 1Marketed / Line Extensions: 1Market Launch: 1PMA Supplement: 1Development & Expansion: 1Assay Menu Expansion: 1Integrated Solution: 1Solution: 1FDA Approved / PMA: 1Pivotal Study (U.S.): 1Not Disclosed (Likely Preclinical/Early Clinical): 1NDA Submitted: 1Approved (Japan): 1Commercial (in China): 1IND-Enabling: 1Phase I-III: 1Phase IV: 1Commercial (China/EU) / Clinical (US): 1Safety & Effectiveness Study: 1Investigational Study: 1Feasibility Trial: 1Randomized Controlled Study: 1Approved / Marketed: 1Discovery / Preclinical: 1Development/Commercial (LDT): 1Next-Generation Development: 1Commercialization: 1Early Exploration: 1FDA Breakthrough Device Designation: 1Screening/Diagnostic: 1Various (Typically Phase 3): 1Early-Stage (FIH/EFS): 1Early Clinical Development: 1First-in-Human (FIH): 1Platform Technology: 1Approved (CE-IVD): 1Phase-3: 1Phase-2: 1Approved (India): 1Clinical-Stage: 1Development/ANVISA Submission: 1Pre-clinical/Concept: 1Unspecified: 1Pre-clinical / Early Feasibility: 1Phase 1-3: 1Research-Use Only: 1Pre-clinical/R&D: 1Breakthrough Device Designation / Commercial: 1Approved (510(k)): 1ANDA Filed/Pre-approval: 1Concept through Development: 1Phase 2/Phase 3: 1Pre-clinical / Early Development: 1Pre-clinical / Concept: 1Development/Regulatory Review: 1Launching: 1Pivotal Trial Completed: 1ANDA Filed/Development: 1IVD Kit: 1First-in-Human / Early Feasibility: 1Investigational / Pre-clinical: 1Development/NDA Filing: 1Development/DMF Submission: 1Pre-clinical / Phase 1 (BA/BE): 1Product Launch: 1Commercial Integration: 1Development/Commercialization: 1Ongoing Development: 1Pre-clinical/Discovery: 1Approved/Commercial (Limited): 1Pivotal Trial Preparation: 1Pre-clinical/Investigational: 1Commercial / PMA Supplement: 1Development / Clinical: 1Pivotal Trial Planning: 1Phase 3 (planned): 1Phase 2 (planned): 1Commercial (EU); Investigational (US): 1Development/Construction: 1Approved (Breakthrough Device): 1Commercial / Generic Development: 1Commercial Launch (EU): 1ANDA Development/Filing: 1Phase 1 / Bioequivalence: 1Investigational / Pivotal Trial: 1Development/Pre-clinical: 1Phase 2B: 1Device Development: 1Clinical Study Completed: 1Early Feasibility / Investigational: 1Feasibility / Early Clinical: 1Development/Regulatory Clearance: 1Commercial Enhancement: 1Post-Market Studies: 1Early Clinical Investigation: 1Pre-clinical/Phase 1: 1Phase 1/Preclinical: 1Pivotal IDE Trial: 1Pivotal IDE: 1Development/Registration: 1N/A (Observational/Mechanistic): 1N/A (Registry): 1Pilot: 1Pilot Observational Study: 1Pre-clinical/Clinical Study: 1IDE Clinical Trial: 1IND Cleared: 1Pre-clinical / Planning: 1First-In-Human (FIH): 1Pilot Study: 1Clinical Stage: 1CE Mark Trial: 1Pilot Studies: 1N/A (Clinical Research Trial): 1Development/Manufacturing: 1Concept to Commercialization: 1Production: 1Pivotal Trial (Planned): 1Research & Development: 1Assay Development: 1Launch/Commercialization: 1Pre-market Approval (FDA Breakthrough): 1Pre-clinical / Feasibility: 1Pre-clinical Trial: 1Early Feasibility / First-in-Human: 1Ongoing R&D: 1Research/Clinical Validation: 1Early Feasibility Study (First-in-Human): 1Development/Commercial Expansion: 1Pre-clinical/Clinical Investigation: 1Not Disclosed (Likely Pre-clinical/Early Clinical): 1Commercial/Research: 1Phase IIb: 1IND filed: 1Pre-clinical/Research: 1Registration/Clinical: 1Pivotal Trial (IDE): 1Pivotal study planned: 1Pivotal/Pre-market: 1Bioequivalence/Registration: 1Post-Market Study: 1Pre-market Clinical Research: 1Regulatory Review (NMPA Green Path): 1CE Mark Obtained; NMPA Green Path: 1NMPA Approved: 1Registration: 1Discovery/Lead Optimization: 1Service: 1Phase 3 / Registration: 1Phase 1/Phase 2: 1Clinical Development (phase unspecified): 1Development/Pre-market: 1Conditionally Approved: 1Research Tool: 1Commercial (cleared): 1IND Accepted: 1NDA: 1IND: 1Market: 1Not Specified (Commercial/Registration): 1Filed/Phase III: 1Preclinical/Phase I: 1Multiple (I-III): 1Development/Clinical Trials: 1Filed/Approved: 1Development/Filed: 1Phase III / Marketed: 1Approved/Phase III: 1Application Submitted: 1BE Studies / Scale-up: 1Preclinical / Early Development: 1Formulation Development: 1CE Mark / FDA Clearance (Ongoing): 1PMA Under Review: 1Commercial / Development: 1ANDA Tentative Approval: 1Process Validation: 1Clinical/Commercial: 1NDA Resubmitted: 1Marketed/Development: 1Commercial & Development: 1Commercial & Line Extensions: 1Early Feasibility/Pivotal: 1Phase IV / Post-Marketing: 1Various Clinical Trials: 1Pre-clinical / Clinical Research: 1Phase III / NDA: 1Phase II / Phase III: 1Phase I / Phase II: 1ANDA Submitted: 1Marketed (ex-US): 1Partnership: 1Phase not specified (Class 1 New Drug): 1Not specified (API/Formulation): 1Discovery to Clinical: 1Preclinical Research: 1Product Development: 1Market Expansion: 1Launch Preparation: 1Clinical Use: 1Not Applicable: 1Phase 1b/2: 1Global Clinical Trial: 1Pre-market (NMPA approved 2025): 1Research/Commercial: 1Approved (China NMPA Review): 1Commercial (CE Mark) / Pivotal Trial (US): 1Investigational / Early Commercial: 1Clinical-stage: 1

Drug	Company	Indication	Phase	Status
Xolatryp	Nyrada	Cardioprotection (STEMI) and Neuroprotection (stroke, TBI)	Phase 1	Active
PCSK9 inhibitor	Nyrada	Hypercholesterolemia (statin‑resistant)	Preclinical	Active
Peripheral nerve pain agent	Nyrada	Neuropathic pain	Preclinical	Active
Autoimmune psoriasis candidate	Nyrada	Psoriasis	Preclinical	Active
EndoForce™ Connector	Phraxis	Endovascular venous anastomosis for arteriovenous graft (AVG) implantation in hemodialysis access	Approved	Active
Epi+Gen CHD™	Cardio Diagnostics Holdings	Risk Assessment for Obstructive Coronary Heart Disease	Commercial	Active
PrecisionCHD™	Cardio Diagnostics Holdings	Diagnosis of Obstructive Coronary Heart Disease	Development	Clinical Validation
Cardiac Cell Therapy Program	StemCardia	Heart Failure	Pre-clinical	Active
Stem Cell Therapy for Blood Diseases	GIOSTAR	Sickle Cell Anemia, Leukemia, Lymphoma, Thalassemia	Not Disclosed	Active
Stem Cell Therapy for Type 1 Diabetes	GIOSTAR	Diabetes (Type 1)	Under Development	Active
Stem Cell Therapy for Neurodegenerative Diseases	GIOSTAR	Alzheimer’s, Parkinson’s, ALS, Multiple Sclerosis	Under Development	Active
Stem Cell Therapy for Autoimmune Diseases	GIOSTAR	Lupus, Crohn's, Vasculitis, Scleroderma	Under Development	Active
FastWave Artero	Fastwave Medical	Peripheral Artery Disease (PAD) - calcific lesions	Pre-clinical	Active
FastWave Sola	Fastwave Medical	Coronary Artery Disease (CAD) - calcific lesions	Pre-clinical	Active
ART001	AccurEdit Therapeutics	ATTR (Transthyretin Amyloidosis)	Phase 1	Active (IIT study initiated Aug 2023, FDA RMAT designation May 2025)
dl-3-n-Butylphthalide (NBP) Soft Capsules	cspc-pharmaceutical	Ischemic Stroke	Phase 3	Active (US trials with FDA orphan drug designation)
Benzonatate Soft Capsules	cspc-pharmaceutical	Cough Suppressant	Commercial	Marketed in US
Azithromycin Preparations	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed
Penem Preparations	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed
Various Penicillin/Cephalosporin Products	cspc-pharmaceutical	Bacterial Infections	Commercial	Marketed
PhysioWave Pro™	Physiowave	Arterial stiffness / cardiovascular risk assessment	commercial	FDA‑cleared
PhysioWave X	Physiowave	Cardiovascular risk stratification, emergency department intake	commercial	market launch
PhysioWave Home	Physiowave	Remote home monitoring of PWV and vital signs	pre‑clinical	in development
Hypertension Pharmacogenomic Test	Geneticure	Treatment guidance for hypertension	Commercial	Active
Rapid Diagnostic Test Platform	ZiJian Biotechnology	Infectious Disease Screening	Commercial	Active
Portable Analyzer Device	ZiJian Biotechnology	Chronic Disease Monitoring	Commercial	Active
ESNtx005	ESN cleer	Rare Cardiomyopathy	Preclinical	Active
TCM Product Portfolio	China SXT Pharmaceuticals	Cardiovascular, Digestive, Metabolic Disorders	Marketed / NDA	Commercial
Generic Drug Portfolio	China SXT Pharmaceuticals	CNS, Cardiovascular, Anti-infective	ANDA / Marketed	Commercial
New TCM Formulations	China SXT Pharmaceuticals	Not Specified	Research / Pre-clinical	Development
New Generic Approvals	China SXT Pharmaceuticals	Various	Application Submitted / BE Stage	Regulatory Review
SofPulse®	Endonovo Therapeutics	Post-operative Pain & Edema	Commercial	Marketed
Electroceutical® Therapy	Endonovo Therapeutics	Ischemic Heart Disease	Preclinical/Exploratory	Active
Polymer Sealed Vascular Grafts	RUA Medical	Large Bore Vascular Repair (e.g., Aortic)	Design & Development	Active
Soft Tissue Patches	RUA Medical	Surgical Repair	Design & Development	Active
Polymeric Tri-leaflet Heart Valve	RUA Medical	Heart Valve Replacement	Concept / Early Development	Active
Authorized Generic of Nucynta® ER (tapentadol)	hikma	Pain Management	Launched	Launched (March 2026)
Authorized Generic of Nucynta® (tapentadol)	hikma	Pain Management	Launched	Launched (February 2026)
Complex Generic Injectables Portfolio	hikma	Various (Oncology Support, Anti-infectives, CNS)	ANDA Filed / Development	Active
Oral Solid Dose Generics Portfolio	hikma	Various (CV, CNS, Diabetes)	ANDA Pending / Development	Active
Branded Specialty Portfolio (MENA)	hikma	Oncology, Diabetes, Cardiovascular, Respiratory	Marketed / Line Extensions	Active
MultiStem	Athersys	Ischemic Stroke	Phase 3	Active (subject to funding)
Elyea (relugolix combo)	Organon (2)	Heavy Menstrual Bleeding with Uterine Fibroids; Endometriosis Pain	Approved	Launched / Commercial Growth
Phexxi	Organon (2)	Non-hormonal Contraceptive	Approved	Launched / Commercial Growth
Orilissa (elagolix)	Organon (2)	Endometriosis Pain	Approved	Launched / Commercial Growth
Biosimilar Aflibercept	Organon (2)	Ophthalmology (nAMD, DME)	Filed	Under Regulatory Review
Biosimilar Denosumab	Organon (2)	Osteoporosis, Bone Metastasis	Phase 3	Active
Biosimilar Ranibizumab	Organon (2)	Ophthalmology (nAMD, DME, RVO)	Phase 3	Active
Biosimilar Ustekinumab	Organon (2)	Plaque Psoriasis, Psoriatic Arthritis, IBD	Phase 3	Active
Biosimilar Bevacizumab	Organon (2)	Oncology	Phase 3	Active